Characteristics | RFS | OS | ||||
---|---|---|---|---|---|---|
Univariable | Multivariable | Univariable | ||||
HR(95% CI) | P value | HR(95% CI) | P value | HR(95% CI) | P value | |
Age(> 60 vs. ≤60 years) | 1.184(0.813–1.724) | 0.378 | 1.398(0.8869–2.251) | 0.168 | ||
Sex (male vs. female) | 1.293(0.863–1.936) | 0.213 | 0.788(0.472–1.313) | 0.360 | ||
Primary tumor location (rectum vs. colon) | 1.037(0.725–1.484) | 0.841 | 1.146(0.725–1.81) | 0.560 | ||
Primary T stage (4 vs. 1–3) | 0.999(0.700-1.427) | 0.998 | 0.909(0.579–1.428) | 0.679 | ||
Nodal metastases (positive vs. negative) | 1.778(1.227–2.578) | 0.002 | 1.889(1.298–2.748) | 0.001 | 1.44(0.902–2.299) | 0.127 |
Primary tumor differentiation (poor vs. well to moderate) | 1.158(0.779–1.721) | 0.467 | 1.581(0.973–2.57) | 0.064 | ||
Timing of metastasis (synchronous vs. metachronous) | 0.74(0.49–1.118) | 0.153 | 0.713(0.427–1.189) | 0.195 | ||
RECIST response (SD/PD vs. PR) | 1.097(0.76–1.583) | 0.621 | 0.988(0.618–1.581) | 0.960 | ||
Preoperative CEA (> 5 vs. ≤ 5 ng/mL) | 1.333(0.922–1.927) | 0.127 | 0.576(0.332–1.001) | 0.051 | ||
Preoperative CA19-9 (> 35 vs. ≤ 35 U/mL) | 1.083(0.714–1.643) | 0.708 | 0.768(0.458–1.289) | 0.318 | ||
Postoperative adjuvant therapy (yes vs. no) | 1.539(1.034–2.291) | 0.033 | 1.578(1.057–2.356) | 0.026 | 1.557(0.997–2.431) | 0.051 |
TBS (> 3 vs. ≤ 3) | 1.18(0.8-1.741) | 0.404 | 1.66(0.966–2.854) | 0.067 | ||
Tumor distribution (bilobar vs. unilobar) | 1.413(0.99–2.018) | 0.057 | 1.652(1.048–2.603) | 0.031 | ||
Postoperative chemotherapy (yes vs. no) | 1.043(0.684-1,591) | 0.845 | 1.233(0.716–2.123) | 0.450 |